Prabhu tells PEOPLE exclusively that she asked the show’s directors to be replaced due to her condition, but ultimately ...

Bristol Myers Squibb has linked its CD19-directed CAR-T cell therapy to sustained clinical responses in people with systemic ...

Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this ...

AI has shown promise by analysing data from patient records to recognise complex patterns within large datasets, which can aid in the ...

Q2 2024 Earnings Call Transcript November 12, 2024 Operator: Good day and thank you for standing by. Welcome to the Roivant ...

Company expects to commence Phase 3 trial of Descartes-08 in patients with myasthenia gravis in 1H2025 following recent meeting with U.S. Food ...

Priovant Therapeutics was formed in 2021 through a partnership between Roivant Sciences and Pfizer (NYSE: PFE) with a focus on developing new treatments for rare autoimmune diseases with high ...

Initiation of patient enrollment expected by year-end 2024 in Ntrust-2, a clinical trial of NKX019 for the treatment of systemic sclerosis, myositis and vasculitis. As previously announced, the ...

The findings, published in Immunity, could lead to new treatments targeting IL-1β ... or patients with the autoimmune disease juvenile dermatomyositis. Mitochondria are normally degraded during ...

To evaluate the influence of environmental factors and prematurity relating to juvenile dermatomyositis (JDM), its course and refractoriness to treatment ... course remained together in the same group ...

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless ...

Additionally, the pipeline includes new treatments for conditions like Cushing ... and a product targeting dermatological myositis, a condition that has historically lacked targeted therapies.